The US Centers for Disease Control and Prevention (CDC) and the US Food and Drug Administration (FDA) have recommended that the US pause the use of Johnson & Johnson's COVID-19 vaccine because of six reported US cases of a rare and severe type of blood clot, CNN news company reported on Tuesday.
According to European health authorities, there have been "four serious cases of unusual blood clots" reported in people who were given the Johnson & Johnson vaccine and like their US counterparts, the European authorities are investigating these cases and that "it is currently not clear" whether there's a causal association between the vaccine and the clots, CNN added.
US health officials are encouraging Americans to get vaccinated as soon as they can, however there are concerns that news coverage about clots being studied in relation to Johnson & Johnson's vaccine might make some Americans more hesitant to get vaccinated for COVID-19.
AbbVie's ELAHERE receives full US FDA approval
Johnson & Johnson's OPSYNVI receives US FDA approval
Outlook Therapeutics receives positive CHMP opinion for ONS-5010 in wet AMD treatment
Human Immunology Biosciences receives ODD from FDA for felzartamab
Eton Pharmaceuticals acquires PKU GOLIKE, expanding rare disease portfolio
Vertex receives FDA clearance for VX-407 Investigational New Drug Application for ADPKD
Phanes Therapeutics receives FDA Fast Track designation for PT886
Bio-Thera Solutions signs new licensing agreement with SteinCares
FDA accepts resubmission of Citius Pharmaceuticals, Inc's BLA for LYMPHIR
GSK Plc reports positive Phase III Jemperli data for endometrial cancer
ImmVira receives FDA Fast Track designation for MVR-T3011 IT